MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
CRISPR Therapeutics AG Accounts Receivables 2011-2025 | CRSP
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables CRISPR Therapeutics AG
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 M | 200 M | - | 305 K | 144 K | 99 K | 88 K | 2.63 M | 3.16 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 88 K | 28.9 M |
Quarterly Accounts Receivables CRISPR Therapeutics AG
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 25 M | - | - | - | 200 M | - | 70 M | - | - | 49 K | 66 K | 143 K | 305 K | 152 K | 150 K | 150 K | 144 K | 144 K | 144 K | 144 K | 99 K | 99 K | 99 K | 99 K | 88 K | 88 K | 88 K | 88 K | 2.63 M | 2.63 M | 2.63 M | 2.63 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 339 K | 339 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 200 M | 49 K | 10 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
1.78 M | $ 4.9 | 4.03 % | $ 813 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 3.21 | -1.38 % | $ 248 M |  USA |
 |
Aptevo Therapeutics
APVO
|
5.22 M | $ 1.06 | -6.22 % | $ 293 K | USA |
 |
Catalyst Biosciences
CBIO
|
1.82 M | $ 13.33 | -5.39 % | $ 878 M | USA |
 |
Celldex Therapeutics
CLDX
|
700 K | $ 27.09 | -1.53 % | $ 1.74 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
54 M | $ 88.51 | 0.59 % | $ 9.14 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
65.5 M | $ 24.35 | 3.07 % | $ 2.88 B | USA |
 |
Acasti Pharma
ACST
|
802 K | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
821 K | - | -15.15 % | $ 60.3 M |  Britain |
 |
Dynavax Technologies Corporation
DVAX
|
45.3 M | $ 10.88 | 0.74 % | $ 1.41 B | USA |
 |
Albireo Pharma
ALBO
|
3.27 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
392 K | - | - | $ 2.17 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
136 M | $ 26.44 | 4.63 % | $ 1.28 B | USA |
 |
Anika Therapeutics
ANIK
|
36 M | $ 9.6 | 0.42 % | $ 141 M | USA |
 |
Eton Pharmaceuticals
ETON
|
3.41 M | $ 15.97 | -4.37 % | $ 410 M | USA |
 |
Exelixis
EXEL
|
265 M | $ 41.27 | 0.95 % | $ 12 B | USA |
 |
Arena Pharmaceuticals
ARNA
|
1.65 M | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
739 K | - | 3.77 % | $ 22.4 M | USA |
 |
Axon Enterprise
AXON
|
18.1 M | $ 551.37 | -2.29 % | $ 41.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
234 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 2.35 | 2.17 % | $ 14.8 M | USA |
 |
Acorda Therapeutics
ACOR
|
17.3 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
1.13 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
676 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
308 M | $ 11.25 | -2.43 % | $ 728 M | USA |
 |
Biogen
BIIB
|
1.4 B | $ 174.69 | 0.34 % | $ 25.4 B | USA |